# The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery

> **NCT02728921** · PHASE4 · COMPLETED · sponsor: **Region Skane** · enrollment: 70 (actual)

## Conditions studied

- Pancreatic Neoplasms
- Urogenital Neoplasm
- Systemic Inflammatory Response Syndrome
- Hypovolemia

## Interventions

- **DRUG:** 5% Albumin infusion 30 min
- **DRUG:** 5% Albumin infusion 3 hours

## Key facts

- **NCT ID:** NCT02728921
- **Lead sponsor:** Region Skane
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-10
- **Final completion:** 2016-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728921, "The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02728921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*